BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 19
• 20
• 21
• 22
• 23
• 24
• 26
• 27
• 28
• 29
• 30

• 

  Business

  Novo Nordisk Lays Off 185 Employees, Hiring 70 in Commercial Reorg

  After falling short of analysts’ expectations in its latest quarter, Novo Nordisk is restructuring its commercial operations as it looks to fend off challenges to its products.

  November 13, 2017

   · 

  2 min read

   · 

  Alex Keown
• 

  Drug Development

  Lessons Learned: One-Time Leader Juno Uses Deaths to Create a Better CAR-T Formula

  Neurotoxicity killed JCAR015 right along with 5 patients in the lead pivotal study, derailing Juno Therapeutics.

  November 13, 2017

   · 

  1 min read
• 

  Job Trends

  Real Estate Developers Eye Boston’s South End for Life Science Campus

  The new space is located just a few miles from Kendall Square that has become the hub of the Boston biotech industry.

  November 13, 2017

   · 

  3 min read

   · 

  Alex Keown
• 

  BioForest

  Top 3 Best Biotechs of 2018

  Noting that biotech stocks have been in “hypergrowth” mode over more than six years, George Budwell, writing for The Motley Fool, looks at three biotech stocks that he would recommend to investors.

  November 13, 2017

   · 

  2 min read

   · 

  Mark Terry
• 

  Biotech Bay

  Top 5 Biosimilars Drug Stocks to Buy Right Now

  During the presidential campaign of 2015-2016, one of the areas that got some of the largest scrutiny was drug pricing, and with good reason.

  November 13, 2017

   · 

  1 min read
• 

  Business

  Tiny Zymeworks Snags $1.4B+ R&D Deal With Drug Giant Johnson & Johnson

  There’s nothing like a billion-plus dollar deal to make investors happy on a Monday.

  November 13, 2017

   · 

  2 min read

   · 

  Alex Keown
• 

  Drug Development

  Argos Surges on Positive Phase III Kidney Cancer Data

  Investors in beleaguered Argos are smiling this morning after the company announced some positive interim data for its Phase III kidney cancer drug, Rocapuldencel-T - a trial that some said should have been scrapped months ago.

  November 13, 2017

   · 

  2 min read

   · 

  Alex Keown
• 

  Career Advice

  Heptares Founder Shares Her Best Life Sciences Career Advice

  Fiona Marshall founded Heptares Therapeutics, which is now one of the leading biotech companies in the UK.

  November 13, 2017

   · 

  3 min read

   · 

  Mark Terry
• 

  Drug Development

  Novartis Showcases 4 Potential Blockbusters in Its Late-Stage Pipeline

  Novartis is not resting on the laurels of having the first-ever-approval for a CAR-T cancer drug, Kymriah.

  November 13, 2017

   · 

  3 min read

   · 

  Alex Keown
• 

  Biotech Bay

  5 Reasons Why Top Scientists Dump Kendall Square for Silicon Valley

  A look at the reasons why top life science talent from Boston’s Kendall Square biotech hub are moving to the San Francisco Bay Area.

  November 13, 2017

   · 

  6 min read

   · 

  Mark Terry